Emily Burke
Acute Care · Baton Rouge, LANPI 1902311053
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 241 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 12.0% — the pattern of someone who eats at a lot of different presentations. Among acute care clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 241 payments — averaging $22.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$661
- AstraZeneca$619
- Mallinckrodt Hospital Products Inc.$565
- Bayer$503
- Vifor Pharma, Inc.$429
- Fresenius USA Marketing, Inc.$369
- plus $2K from 22 others
What the payments were for
- Food & beverage$5,43599%
- Education$741%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 30 | $661 |
| AstraZeneca(2 entities) | 30 | $619 |
| Mallinckrodt Hospital Products Inc. | 19 | $565 |
| Bayer | 19 | $503 |
| Vifor Pharma, Inc. | 19 | $429 |
| Fresenius USA Marketing, Inc. | 18 | $369 |
| OPKO Pharmaceuticals, LLC | 18 | $286 |
| Amgen(2 entities) | 10 | $219 |
| Akebia Therapeutics Inc | 9 | $215 |
| Calliditas Therapeutics US Inc. | 11 | $207 |
| Sanofi | 8 | $195 |
| Novartis | 6 | $168 |
| Nxstage Medical, Inc. | 2 | $152 |
| Aurinia Pharma U.S., Inc. | 7 | $147 |
| Medtronic | 3 | $106 |
| ANI Pharmaceuticals, Inc. | 5 | $97 |
| Baxter Healthcare | 1 | $86 |
| Ardelyx, Inc. | 4 | $83 |
| Boehringer Ingelheim | 4 | $69 |
| Novo Nordisk | 2 | $66 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $54 |
| Lilly USA, LLC | 3 | $50 |
| Travere Therapeutics, Inc. | 2 | $36 |
| Ultragenyx Pharmaceutical Inc. | 2 | $33 |
| Daiichi Sankyo Inc. | 2 | $27 |
| GSK | 2 | $25 |
| Veloxis Pharmaceuticals, Inc. | 1 | $22 |
| Pharmacosmos Therapeutics Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,508 in reported general payments places this provider in the 90th percentile of 248 acute care providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 132 | $339,028 |
| AuryxiaFerric Citrate | 103 | $206,380 |
| JardianceEmpagliflozin | 41 | $27,308 |
| Sevelamer Carbonate | 135 | $20,150 |
| FarxigaDapagliflozin Propanediol | 22 | $15,345 |
| VeltassaPatiromer Calcium Sorbitex | 13 | $14,954 |
| LokelmaSodium Zirconium Cyclosilicate | 18 | $13,871 |
| Lanthanum Carbonate | 18 | $13,581 |
| Doxazosin Mesylate | 25 | $527 |
| Hydralazine Hcl | 40 | $519 |
| Calcitriol | 52 | $497 |
| Furosemide | 110 | $488 |
| Potassium Chloride | 24 | $431 |
| Nifedipine ErNifedipine | 20 | $393 |
| Losartan Potassium | 60 | $370 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $369 | $339,028132 claims |
| Akebia Therapeutics IncAuryxia | $215 | $206,380103 claims |
| AstraZenecaFarxiga, Lokelma | $619 | $29,21640 claims |
| Boehringer IngelheimJardiance | $69 | $27,30841 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 248 acute care providers in Louisiana.
Other acute care in Baton Rouge
- Chad KlugBaton Rouge$8K
- Mallory PriceBaton Rouge$3K
- Precious HodgesLafayette$70K
- Brinton FegleyShreveport$61K
- Charles JarreauNew Orleans$40K
- Jeremy DavisShreveport$35K
- Heather MecomShreveport$17K
- Jeremy TerroLafayette$11K
- Mary HireShreveport$11K
- Jacquelyn CosterHouma$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.